This means that it could be used in combination with GLP-1s to possibly enhance weight loss or simply offer an alternative to these drugs. Second, and one reason why someone might choose a CB1 drug ...

This clinical trial is a randomized, double-blind study designed to enroll 120 patients across four treatment groups. The ...

There is currently no approved treatment for PWS. CB1 inverse agonists have been shown to reduce appetite, and induce weight loss by several mechanisms, including increasing energy expenditure and ...

Skye Bioscience (SKYE) announced preliminary data from a diet-induced obesity model in mice. Skye’s CB1-inhibiting antibody, nimacimab, ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

The data are being presented as a Poster Presentation titled: “Induction and Maintenance Regimens with CB1 Inverse Agonist ... that CRB-913 provides additive weight loss when combined with ...